Thea Pharma Announces Activities and Events at the Upcoming American Academy of Ophthalmology (AAO) Annual Meeting

Thea Pharma announced that the company will attend and participate in a number of meetings and events taking place at or in association with the American Academy of Ophthalmology Meeting, being held Sept. 30 to Oct. 3 at McCormick Place in Chicago. Thea will exhibit its flagship products in the booth and be featured in several key events throughout the weekend.

•  AAO Congress 2022 exhibit highlights (booth #5517):

• Ivizia is a branded line of preservative-free over-the-counter (OTC) products for dry eye and eyelid hygiene. Ivizia Lubricant eye drops are comprised of a unique formulation of povidone, trehalose (3%) and hyaluronic acid (0.15%), that work together to alleviate dry eye symptoms and improve the tear film and decrease ocular surface inflammation. The full line also includes Ivizia Lubricant Eye Gel for overnight use and Ivizia Gentle Eyelid Cleansing products to promote healthy eye lids.
• AcellFX (acellular amniotic membrane) is a human amniotic membrane that provides a protective environment for repair of the cornea and conjunctiva, allowing recellularization to occur and the ocular surface to return to a healthier state[1-3]. AcellFX is gently processed without harsh chemicals and ready for immediate use without thawing or rinsing and is shelf stable for up to 5 years. It offers doctors the added flexibility of multiple sizes and application techniques to fit a variety of needs for cornea and conjunctiva repair.
• Zioptan (tafluprost 0.0015%) is a prostaglandin analog that reduces intraocular pressure in patients with glaucoma or ocular hypertension. The preservative-free formulation does not contribute to ocular surface toxicity, stinging and redness—side effects that can decrease both patient compliance and quality of life.

•  World Cornea Congress VIII, Sept. 28 to 29 (booth B26) – At this international meeting where cornea, cataract and refractive specialists discuss groundbreaking research and techniques, Thea will feature the innovative Ivizia product line and AcellFX.

•  Eyecelerator, Sept. 29 – Thea is a proud sponsor of Eyecelerator, a meeting focused on innovation and attended by more than 500 “industry-leading clinicians, investors, global executives and mission-driven entrepreneurs who are disrupting eye care.”

• Ophthalmic World Leaders (OWL) Signature Event & Awards Ceremony, Oct. 2 – At this year’s event, Thea’s US President, Susan Benton, has been nominated as a finalist for the prestigious Catalyst Award by industry peers. OWL’s Catalyst Award honors an individual who has contributed significantly to helping others advance their career in eye care. 

“We’re very excited for the US team to be attending this year’s AAO meeting, where doctors meet to share, discuss and accelerate the latest advances in ocular health,” said Susan Benton, Thea’s U.S. President. “Thea is a world leader in preservative-free ophthalmic products—an important product attribute when treating patients with chronic ocular diseases and conditions.  We’ve expanded our product portfolio and our presence in the U.S., and we look forward to seeing and meeting with attendees to discuss how we can help improve upon current therapeutic options for their patients.